Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 1211-1220 of 2859 for cancer

Edit search filters
  1. A Study Of Nivolumab And Multi-fraction Stereotactic Radiosurgery With Or Without Ipilimumab In Treating Participants With Recurrent Grade II-III Meningioma

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  2. Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

    Rochester, MN

  3. Nivolumab And Brentuximab Vedotin In Treating Older Patients With Untreated Hodgkin Lymphoma

    Rochester, MN

  4. A Study Of Atezolizumab Alone Or Combined With Immunomodulatory Drug And/or Daratumumab In Multiple Myeloma Patients

    Scottsdale/Phoenix, AZ, Jacksonville, FL

  5. A Study Of SAR442085 In Relapsed Or Refractory Multiple Myeloma

    Rochester, MN

  6. Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye

    Rochester, MN

  7. ONC201 In H3 K27M-mutant Diffuse Glioma Following Radiotherapy (The ACTION Study)

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  8. A Dose Finding And Safety Study Of CC-220, Alone And In Combination With An Anti-CD20 Monoclonal Antibody (MAb) In Subjects With Relapsed Or Refractory Lymphomas

    Scottsdale/Phoenix, AZ, Rochester, MN

  9. Lenalidomide Or Observation In Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

    Rochester, MN

  10. A Study To Evaluate Tazemetostat Combined With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma

    Jacksonville, FL, Rochester, MN

.

Mayo Clinic Footer